Deglycosylation or partial removal of HIV-1 CN54 gp140 V1/V2 domain enhances env-specific T cells

AIDS Research and Human Retroviruses

Volumn 25, Issue 6, 2009, Pages 607-617

  Wan, Yanmin ^a,b   Liu, Lianxing ^a   Wu, Lan ^a,c   Huang, Xianggang ^a   Ma, Liying ^a   Xu, Jianqing ^a,b,d  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b FUDAN UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Scientific Research Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; GLYCOPROTEIN GP 140; PLASMID VECTOR; RECOMBINANT TIANTAN VACCINIA VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BAGG ALBINO MOUSE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEGLYCOSYLATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SPLEEN CELL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; ANIMAL; BLOOD; CHINA; GENETICS; GLYCOSYLATION; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; CHINA; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GLYCOSYLATION; HIV ANTIBODIES; HIV-1; MICE; MICE, INBRED BALB C; SEQUENCE DELETION; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 67651177546     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0289     Document Type: Article

References (48)

1. Burns DP, and Desrosiers RC: Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. Curr Top Microbiol Immunol 1994;188:185-219.
2. Burton DR: Antibodies, viruses and vaccines. Nat Rev Immunol 2002;2:706-713.
3. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Po-lonis VR, et al.: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 2002;76:9035-9045.
4. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al.: HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:678-682.
5. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
6. Yang ZY, Chakrabarti BK, Xu L, Welcher B, Kong WP, Leung K, et al.: Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 Envelope. J Virol 2004;78:4029-4036.
7. Guillon C, Schutten M, Boers PH, Gruters RA, and Os-terhaus AD: Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J Virol 2002;76:2827-2834.
8. Parren PW, Moore JP, Burton DR, and Sattentau QJ: The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. AIDS 1999;13(Suppl A):S137-S162.
9. Wyatt R, and Sodroski J: The HIV-1 Envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280: 1884-1888.
10. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 Envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
11. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, and Nunberg JH: Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. Science 1999;283: 357-362
12. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, et al.: Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 Envelope protein. Proc Natl Acad Sci USA 1999;96:6359-6364.
13. Reitter JN, Means RE, and Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nat Med 1998;4:679-684.
14. Ly A, and Stamatatos L: V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 Envelope facilitates interaction of this protein with CD4 and CCR5 receptors and rotects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol 2000;74:6769-6776.
15. Chakrabarti BK, Kong WP, Wu BY, Yang ZY, Friborg J, Ling X, et al.: Modifications of the human immunodeficiency virus Envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002;76:5357-5368.
16. Malenbaum SE, Yang D, Cavacini L, Posner M, Robinson J, and Cheng-Mayer C: The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 Envelopes with CD4 and chemokine receptors. J Virol 2000;74:11008-11016.
17. Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, et al.: Structure-based,targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003;313:387-400.
18. Quinones-Kochs MI, Buonocore L, and Rose JK: Role of N-linked glycans in a human immunodeficiency virus Envelope glycoprotein: Effects on protein function and the neutralizing antibody response. J Virol 2002;76:4199-4211.
19. Reynard F, Fatmi A, Verrier B, and Bedin F: HIV-1 acute infection Env glycomutants designed from 3D model: Effects on processing, antigenicity, and neutralization sensitivity. Virology 2004;324:90-102.
20. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, and Robinson J: Functional and immunologic characterization of human immunodeficiency virus type 1 Envelope glycoproteins containing deletions of the major variable regions. J Virol 1993;67:4557-4565.
21. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, and Wyatt R: Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 Envelope glycoprotein. J Virol 1997;71: 9808-9812.
22. Kim YB, Han DP, Cao C, and Cho MW: Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 Envelope glycoproteins to elicit neutralizing antibodies. Virology 2002;305:124-137.
23. Yang Z, Chakrabarti BK, Xu L, Welcher B, Kong WP, Leung K, et al.: Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 Envelope. J Virol 2004;78:4029-4036.
24. Stamatatos L, and Cheng-Mayer C: An Envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998;72:7840-7845.
25. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, and Blanchard J: The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) Envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hy-pervariable region. J Virol 2001;75:5526-5540.
26. Kiszka I, Kmieciak D, Gzyl J, Naito T, Bolesta E, Sieron A, et al.: Effect of the V3 loop deletion of Envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates. J Virol 2002;76:4222-4232.
27. Gzyl J, Bolesta E, Wierzbicki A, Kmieciak D, Naito T, Honda M, et al.: Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 Envelope glycoprotein on the breadth of gp160-specific immune responses. Virology 2004;318:493-506.
28. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Mal-enbaum SE, Burke B, et al.: The V1, V2, and V3 regions of the uman immunodeficiency virus type 1 Envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 2005;79:9069-9080.
29. Parren, PW, Moore JP, Burton DR, and Sattentau QJ: The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. AIDS 1999;13(Suppl A):S137-S162.
30. Zolla-Pazner S: Improving on nature: Focusing the immune response on the V3 loop. Hum Antibodies 2005;14: 69-72.
31. Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, et al.: Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epi-tope masking. J Virol 2005;79:780-790.
32. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, and Sodroski J: Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loop. J Virol 2001;75:3435-3443.
33. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al.: A conserved HIV gp120 gly-coprotein structure involved in chemokine receptor binding. Science 1998;280:1949-1953.
34. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, and Sodroski J: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995; 69:5723-5733.
35. Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, et al.: Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002;76:6138-6146
36. Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, et al.: Polyvalent Envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/ human immunodeficiency virus infection in pigtailed macaques. J Virol 2001;75:2224-2234.
37. Bogers WM, Niphuis H, Haaft P, Laman JD, Koornstra W, and Heeney JL: Protection from HIV-1 Envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge. AIDS 1995;9:F13-F18.
38. Dunn CS, Hurtrel B, Beyer C, Gloeckler L, Ledger TN, Moog C, et al.: Protection of SIVmac-infected macaques against superinfection by a simian immunodeficiency virus expressing Envelope glycoprotein of HIV type 1. AIDS Res Hum Retroviruses 1997;13:913-922.
39. Tagmyer TL, Craigo JK, Cook SJ, Issel CJ, and Montelaro RC: Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J Gen Virol 2007;88:1324-1336.
40. Gu S, Huang T, Miao YH, Zhao YH, Han CH, Xiao Y, et al.: A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin Med Sci J 1991;6:241-243.
41. Zhao K, et al.: Archive of TianTan Vaccinia Research, 1975. ISBN No: R979.9.
42. Li HS, Liu Y, Li DF, Zhang RR, Tang HL, Zhang YW, et al.: Enhancement of DNA vaccine-induced immune responses y a 72-bp element from SV40 enhancer. Chin Med J 2007;120:496-502.
43. Cole KS, Paliotti MJ, Murphey-Corb M, and Montelaro RC: Maturation of Envelope-specific antibody responses to linear determinants in monkeys inoculated with attenuated SIV. J Med Primatol 2000;29:220-230.
44. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, et al.: Evolution of Envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997;71:5069-5079.
45. Earl P, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, et al.: Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001;75:645-653.
46. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al.: Human monoclonal antibody 2G12: A distinctive neutralization epitope on the gp120 glycoprotein f human immunodeficiency virus type 1. J Virol 1996;70:1100-1108.
47. Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, Weng J, et al.: Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 Envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998;14:151-155.
48. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, et al.: Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009;457:87-91.